Mitochondrial response precedes intracellular accumulation of α-synuclein in Parkinson’s disease
Objective: To investigate the expression of mitochondrial COX-IV during the progression of Parkinson's disease. Background: Parkinson's disease (PD) is a neurodegenerative disease characterized by the…Chronic cerebral hypoperfusion accelerates cognitive dysfunction and microvascular impairment in the MPTP mouse model of Parkinson’s disease
Objective: To evaluate cerebral hypoperfusion on cognitive dysfunction and related microvascular impairment in the MPTP mouse model. Background: Vascular pathology and Parkinson's disease (PD) pathology…Lessons learned from the Nilotinib trial: Cardio-vascular conditions in parkinsonism
Objective: A retrospective records review of 9 patients that failed screening for a clinical trial was performed to examine the co-morbid cardiac manifestations of PD…Modulating neuronal activity in dopaminergic neurons to promote their survival
Objective: To manipulate the activity of dopaminergic (DA) neurons in culture using pharmacological and molecular tools to promote their survival. Background: Parkinson's disease is a…Constipation in early de novo Parkinson’s disease: Prevalence and correlates with clinical features, imaging and non-imaging biomarkers
Objective: To explore the association between constipation and clinical features, imaging and non-imaging biomarkers in early de novo (untreated) Parkinson's disease (PD) patients. Background: Constipation…A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity
Objective: To develop a novel transgenic C. elegans model to study dopaminergic neurodegeneration mediated by alpha-synuclein. Background: Targeting alpha-synuclein could be a disease-modifying strategy for…Difference of REM sleep behavior disorder between the onset of before and after Parkinson’s disease
Objective: It is not clear that the onset of RBD (REM sleep behavior disorder) affect clinical characteristics of PD. A cross section study comparing clinical…Cell-surface expression of dopamine transporter facilitates the uptake of α-synuclein
Objective: We determined whether increased expression of DAT have an impact on the uptake of α-synuclein (αS). Background: The endocytosis of dopamine transporter (DAT) controls…Bcr-Abl tyrosine-kinase inhibitors (B-ATKI) and Parkinson’s disease (PD)
Objective: Looking through the Kaiser Permanente National Parkinson's disease Registry, generated through the electronic medical records (EMR), we took a first step in looking at…Optimization of 6-hydroxydopamine animal model of early stage Parkinson´s disease for the assessment of neurorestorative therapies
Objective: To optimize a simple unilateral partial 6-hydroxydopamine (6-OHDA) lesion protocol that would produce 40-60% striatal dopamine (DA) depletion with detectable motor deficits and to…